SEARCH

SEARCH BY CITATION

References

  • 1
    Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988; 4: 51740.
  • 2
    Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 1986; 78: 164857.
  • 3
    Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH Kahn SE. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 100515.
  • 4
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 267469.
  • 5
    Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 52546.
  • 6
    Diez JJ, Iglesias P. The role of novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293300.
  • 7
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita, S, Okubo, K, Matsubara, K, Muraguchi, M, Ohmoto, Y, Funahashi, T, Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 7983.
  • 8
    Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002; 277: 195219.
  • 9
    Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 2003; 52: 177985.
  • 10
    Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. JClin Endocrinol Metab 2001; 86: 381519.
  • 11
    Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 244250.
  • 12
    Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froquel, P, Foufelle, F, Ferre, P, Carling, D, Kimura, S, Nagai, R, Kahn, BB, Kadowaki, T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 128895.
  • 13
    Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 18848.
  • 14
    Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 27649.
  • 15
    Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signalling through a cAMP-dependent pathway. Circulation 2000; 102: 1296301.
  • 16
    Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 11027.
  • 17
    Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 11603.
  • 18
    Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, Trichopoulos D. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003; 88: 9937.
  • 19
    Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005; 65: 116872.
  • 20
    Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; 66: 19.
  • 21
    Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer—a quantitative review. Br J Cancer 2001; 85: 98490.
  • 22
    Mellemgaard A, Lindbland P, Schlehofer B, Bergstrom R, Mandel JS, McCredie M, McLaughlin JK, Niwa S, Odaka N, Pommer W. International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int J Cancer 1995; 60: 3504.
  • 23
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 57991.
  • 24
    Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G, McLaughlin JK, Nyren O, Adami HO. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42: 10712.
  • 25
    Chow WH, Gridley G, Fraumeni JFJr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 130511.
  • 26
    Stoerkel S, Hinkel A. Epithelial tumors of the kidney. In: Belldegrun A, Ritchie A, Figlin R, Oliver RTD, Vaughan EDJr, eds. Renal and adrenal tumors. New York: Oxford University Press, 2003. 4054.
  • 27
    Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH Yarbo JW. AJCC cancer staging manual, 5th edn. Philadelphia: Lippincot-Raven, 1997. 2312.
  • 28
    Medeiros LJ, Jones EC, Aizawa S, Aldape HC, Cheville JC, Goldstein NS, Lubensky IA, Ro J, Shanks J, Pacelli A, Jung SH. Grading of renal cell carcinoma: workgroup no. 2. Union internationale contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer 1997; 80: 9901.
  • 29
    Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. Classification of renal cell carcinoma: workgroup no. 1. Union internationale contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer 1997; 80: 9879.
  • 30
    Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D, the Childhood Hematoloty Oncology Group. Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 2006; 94: 15660.
  • 31
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97: 168894.
  • 32
    SAS Institute Inc. SAS/STAT User's Guide, Version 6, 4th edn., SAS Institute Inc, Cary, NC, 1989.
  • 33
    Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 27082.
  • 34
    Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 11518.
  • 35
    Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 578.
  • 36
    Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein–cholesterol, independent of body mass index, in the Japanese population. Clin Sci 2002; 103: 13742.
  • 37
    Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting of leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 482331.
  • 38
    Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 45969.
  • 39
    Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10( Suppl 2): 97S104S.
  • 40
    Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 442633.
  • 41
    Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005; 11: 46672.
  • 42
    Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94: 12215.
  • 43
    Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno, NH, Shibata Y, Terauchi Y, Froquel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki, T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 7629.
  • 44
    Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family soluble defense collagens, negatively regulates the growth of the myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 172332.
  • 45
    Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci 2004; 101: 247681.
  • 46
    Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 23952.
  • 47
    Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 3336.
  • 48
    Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 2005; 333: 7987.
  • 49
    Levy DE, Darnell JE,Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 65162.